Home / Economy / News / Is India right in recommending HCQ despite the uncertainties around it?

Is India right in recommending HCQ despite the uncertainties around it?

HCQ was dropped from the solidarity trial that WHO was conducting as a part of a global effort in May.

hydroxychloroquine, hcq, drugs, coronavirus, pharma

Premium

HCQ was dropped after peer-reviewed medical journal The Lancet said that HCQ can lead to increased mortality rates and came with risks of adverse effects like cardiac arrhythmia.

Sohini Das Mumbai

4 min read Last Updated : Jun 05 2020 | 10:59 AM IST

The World Health Organisation (WHO) has resumed the trials on hydroxychloroquine (HCQ), the drug that became famous after the US President spoke about its efficacy. HCQ was dropped from the solidarity trial that WHO was conducting as a part of a global effort in May.

This was done after peer reviewed medical journal The Lancet said that HCQ can lead to increased mortality rates and came with risks of adverse effects like cardiac arrhythmia. On Wednesday, The Lancet red-flagged the study. It has issued a statement of concern now after more than 100 scientists across the world flagged discrepancies in

Topics : Coronavirus Hydroxychloroquine World Health Organisation Donald Trump Lancet report rheumatoid arthritis Malaria Pharma Companies Pharmaceuticals Health Ministry

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in